Marinus to present Ganaxolone DATA at American academy of neurology annual meeting
April 18 2017 - 7:30AM
Platform Presentation of Phase 2 Data in Fragile
X Syndrome
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical
company dedicated to the development of innovative therapeutics to
treat epilepsy and neuropsychiatric disorders, announced today that
data on ganaxolone, Marinus’ positive allosteric modulator of
GABAA, will be presented at the 69th Annual Meeting of the American
Academy of Neurology in Boston, MA on April 22-28, 2017.
The presentation details are as follows:
Title: A Randomized
Double-blind, Placebo-controlled, Cross-over Trial of Ganaxolone in
Children and Adolescents with Fragile X SyndromeAbstract
#: 1232Platform Presentation
#: 005Platform Presentation Session:
S46: Child Neurology: Molecular Biology of Clinical
TrialsDate and Time: Thursday, April 27,
2017 @ 4:18 pm ETPresenting Author: Julia Tsai,
Ph.D.
Title: A Multi-center,
Open-label Trial of Ganaxolone in Children with PCDH19 Epilepsy
Abstract #: 3477Session #:
Poster Session 5Poster #: 236Date and
Time: Thursday, April 27, 2017 8:30 am – 7:00 pm
ETPresenting Author: Jaakko Lappalainen, MD
Title: A Multi-center,
Double-blind, Randomized, Placebo-controlled Phase 3 Trial to
Determine the Efficacy and Safety of Ganaxolone as Adjunctive
Therapy for Adults with Drug-Resistant Focal Onset Seizures
Abstract #: 3476Session #:
Poster Session 5Poster #: 237Date and
Time: Thursday, April 27, 2017 8:30 am – 7:00 pm
ETPresenting Author: Jaakko Lappalainen, MD
About Ganaxolone
Ganaxolone, a positive allosteric modulator of
GABAA, is being developed in three different dose forms
(intravenous, capsule, and liquid) intended to maximize therapeutic
reach to adult and pediatric patient populations in both acute and
chronic care settings. Ganaxolone exhibits antiseizure and
antianxiety actions via its effects on synaptic and extrasynaptic
GABAA receptors. Ganaxolone has been studied in more
than 1,500 subjects, both pediatric and adult, at therapeutically
relevant dose levels and treatment regimens for up to two years. In
these studies, ganaxolone was generally safe and well tolerated.
The most commonly reported adverse events were somnolence,
dizziness and fatigue.
About Marinus
Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a
biopharmaceutical company dedicated to the development of
ganaxolone, which offers a new mechanism of action, demonstrated
efficacy and safety, and convenient dosing to improve the lives of
patients suffering from epilepsy and neuropsychiatric disorders.
Ganaxolone is a positive allosteric modulator of GABAA that acts on
a well-characterized target in the brain known to have both
antiseizure and antianxiety effects. Ganaxolone is being developed
in three different dose forms (IV, capsule and liquid) intended to
maximize therapeutic reach to adult and pediatric patient
populations in both acute and chronic care settings. Marinus is
currently evaluating ganaxolone in orphan pediatric indications for
the treatment of genetic seizure and behavior disorders, and
preparing to initiate Phase 2 studies in status epilepticus, an
orphan indication, and postpartum depression. For more information
visit www.marinuspharma.com. Please follow us on Twitter:
@MarinusPharma.
Forward-Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Marinus, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words such as “may”, “will”, “expect”, “anticipate”,
“estimate”, “intend”, “believe”, and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. Examples of forward-looking statements contained
in this press release include, among others, statements regarding
our interpretation of preclinical studies, development plans for
our product candidate, including the development of dose forms, the
clinical trial testing schedule and milestones, the ability to
complete enrollment in our clinical trials, interpretation of
scientific basis for ganaxolone use, timing for availability and
release of data, the safety, potential efficacy and therapeutic
potential of our product candidate and our expectation regarding
the sufficiency of our working capital. Forward-looking statements
in this release involve substantial risks and uncertainties that
could cause our clinical development programs, future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such
risks and uncertainties include, among others, the uncertainties
inherent in the conduct of future clinical trials, the timing of
the clinical trials, enrollment in clinical trials, availability of
data from ongoing clinical trials, expectations for regulatory
approvals, and other matters, including the development of
formulations of ganaxolone, that could affect the availability or
commercial potential of our drug candidates. Marinus
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of the Company in general, see filings
Marinus has made with the Securities and Exchange Commission.
CONTACT:
Lisa M. Caperelli
Executive Director, Investor & Strategic Relations
Marinus Pharmaceuticals, Inc.
484-801-4674
lcaperelli@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Sep 2023 to Sep 2024